Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV001580222 | SCV001809856 | pathogenic | Glanzmann thrombasthenia | 2021-04-20 | reviewed by expert panel | curation | The ITGA2B intronic variant NM_000419.5:c.2348+5G>C is predicted by multiple in silico tools to lead to loss of the proximal canonical splice donor. In vitro minigene assays and sequence analysis (PMID: 25728920) support these predictions, suggesting the variant results in nearly complete in-frame skipping of exon 23, reducing the protein length by 27 amino acid residues (p.Ser756Gly783delinsArg). Additional functional studies in COS-7 cells indicate exon 23 skipping leads to significantly reduced surface protein expression (<10% compared to wild type) due to a block in integrin maturation (PMID: 25728920). This variant has been observed in homozygosity in an individual (GT8 in PMID: 25728920) with a phenotype specific for Glanzmann's thrombasthenia (GT). Furthermore, the variant is absent from control population databases. In summary, this variant meets criteria to be classified as pathogenic for GT. GT-specific criteria applied: PP4_strong, PM4, PS3_moderate, PP3, PM2_supporting, PM3_supporting. |